Active, not recruitingPHASE1, PHASE2NCT06591273
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial
Studying Chronic graft versus host disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Services Institute of Medical Sciences, Pakistan
- Principal Investigator
- Dr Hira Tariq, MBBS, FCPS DermaServices Institute of Medical Sciences, Pakistan
- Intervention
- Infliximab-dyyb Biosimilar (Remsima)(biological)
- Enrollment
- 104 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2023 – 2024
Study locations (1)
- Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital, Lahore, Punjab Province, Pakistan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06591273 on ClinicalTrials.govOther trials for Chronic graft versus host disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07394608Paired Non-invasive VNS in Adolescent Cerebral Palsy RehabilitationIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT07124078A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)Incyte Corporation
- RECRUITINGEARLY PHASE1NCT07355868Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell TherapyRegend Therapeutics
- RECRUITINGNANCT06857929"Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition"IMDEA Food
- RECRUITINGPHASE1NCT07389044A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis BIntegerBio
- RECRUITINGNCT07127926Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHDM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT07138196A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host DiseaseQurient Co., Ltd.
- ACTIVE NOT RECRUITINGNCT07321080Central Sensitisation in Nociceptive and Neuropathic PainIRCCS Centro Neurolesi Bonino Pulejo